---
title: "JD Health International, Inc. (6618) Gets a Buy from CICC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278200708.md"
description: "In a report released yesterday, from CICC maintained a Buy rating on JD Health International, Inc., with a price target of HK$66.20. The company’s shares closed yesterday at HK$48.40.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for JD Health International, Inc. with a HK$74.40 average price target."
datetime: "2026-03-07T05:46:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278200708.md)
  - [en](https://longbridge.com/en/news/278200708.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278200708.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278200708.md) | [繁體中文](https://longbridge.com/zh-HK/news/278200708.md)


# JD Health International, Inc. (6618) Gets a Buy from CICC

In a report released yesterday, from CICC maintained a Buy rating on JD Health International, Inc., with a price target of HK$66.20. The company’s shares closed yesterday at HK$48.40.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for JD Health International, Inc. with a HK$74.40 average price target.

### Related Stocks

- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [JD-SW (09618.HK)](https://longbridge.com/en/quote/09618.HK.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md)
- [ChinaAMC CSI All Share Health Care Devices ETF (562600.CN)](https://longbridge.com/en/quote/562600.CN.md)
- [Maxwealth CSI All Share Medical Apparatus and Instruments ETF (159883.CN)](https://longbridge.com/en/quote/159883.CN.md)
- [JD HEALTH (06618.HK)](https://longbridge.com/en/quote/06618.HK.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [08:03 ETDecentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health](https://longbridge.com/en/news/277468910.md)
- [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/en/news/277818646.md)
- [Fangzhou, Youcare Partner To Advance AI In Chronic Disease Care](https://longbridge.com/en/news/277337723.md)
- [Procode AI launches from stealth with $4M and the acquisition of The Auctus Group to bring AI-powered RCM to private practice surgeons](https://longbridge.com/en/news/277485008.md)
- [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/en/news/277695972.md)